...Irina Amitai; Ronit Gurion; Pia Raanani; Iuliana Vaxman; Moshe Yeshurun; Hila Magen; Anat Gafter-Gvili; Liat Shargian Introduction: High-dose therapy with melphalan followed by autologous stem cell transplant in the upfront setting (upfront ASCT) has significantly improved clinical outcomes...

...Inbar Cohen; Iuliana Vaxman; Morie A. Gertz Background: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become part of standard of care (SOC) in newly diagnosed multiple myeloma. In this review, we provide a historical perspective on ASCT since its introduction...

.... The type of infections seen were mainly viral (Table 5 ). Table 4. Toxicities: patients ( n ) with noninfectious toxicities of grades 3 and 4 Autologous stem cell transplant Bortezomib Posttransplant therapy Vorinostat Relapse of multiple myeloma (MM) is one of the major causes...

...Ghulam Rehman Mohyuddin; Ashley Elizabeth Clark; John Roller; Leyla Shune; Tara Lin; Neil Dunavin; Ajoy Dias; Siddhartha Ganguly; Sunil Abhyankar; Joseph McGuirk; Anurag Singh Background: Surveillance scans performed after autologous stem cell transplant (auto-HCT) for patients with Hodgkin disease...

... effects of a given treatment modality because it tends to diminish the actual difference between treatments. The second step is to assess the following confounders: timing of study entry for patients in the alloHSCT versus conventional chemotherapy or autologous stem cell transplant (ASCT) arms...